Granted Patent
B2
US 12,384,789 · App. 17/723,163 · Granted Aug 12, 2025
Compounds for treating Huntington's disease
Inventors:
Matthew G. Woll (Dunellen, NJ); Lukiana Amedzo (Somerset, NJ); Suresh Babu (Pennington, NJ); Scott J. Barraza (Piscataway, NJ); Anuradha Bhattacharyya (Edison, NJ); Gary Mitchell Karp (Princeton Junction, NJ); Anthony R. Mazzotti (Rahway, NJ); Jana Narasimhan (Scotch Plains, NJ); Jigar Patel (Edison, NJ); Anthony Turpoff (Hillsborough, NJ); Zhenrong Xu (Chalfont, PA)
Assignee:
PTC Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
Claims (16)
1. A compound of Formula (Ig1), Formula (Ii1), or Formula (Im1):
or a form thereof, wherein:
R 1 is heterocyclyl or heterocyclyl-amino, wherein heterocyclyl is selected from the group consisting of azetidinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, azepanyl, 1,4-diazepanyl, 1,2,5,6-tetrahydropyridinyl, 1,2,3,6-tetrahydropyridinyl, hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, (3aR,6aR)-hexahydropyrrolo[3,4-b]pyrrol-(1H)-yl, hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, (3aS,6aS)-hexahydropyrrolo[3,4-b]pyrrol-(2H)-yl, hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, (3aR,6aS)-hexahydropyrrolo[3,4-c]pyrrol-(1H)-yl, octahydro-5H-pyrrolo[3,2-c]pyridinyl, octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridinyl, hexahydropyrrolo[1,2-a]pyrazin-(2H)-one, hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (7R,8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aS)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-hexahydropyrrolo[1,2-a]pyrazin-(1H)-yl, hexahydro-1H-cyclobuta[1,2-c:1,4-c′]dipyrrol-(3H)-yl, (8aS)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, (8aR)-octahydropyrrolo[1,2-a]pyrazin-(1H)-yl, octahydro-2H-pyrido[1,2-a]pyrazinyl, 3-azabicyclo[3.1.0]hexyl, (1R,5S)-3-azabicyclo[3.1.0]hexyl, 8-azabicyclo[3.2.1]octyl, (1R,5S)-8-azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, (1R,5S)-8-azabicyclo[3.2.1]oct-2-enyl, 9-azabicyclo[3.3.1]nonyl, (1R,5S)-9-azabicyclo[3.3.1]nonyl, 2,5-diazabicyclo[2.2.1]heptyl, (1S,4S)-2,5-diazabicyclo[2.2.1]heptyl, 1,4-diazabicyclo[3.1.1]heptyl, 3,6-diazabicyclo[3.2.0]heptyl, 2,5-diazabicyclo[2.2.2]octyl, 1,4-diazabicyclo[3.2.1]octyl, 3,8-diazabicyclo[3.2.1]octyl, (1R,5S)-3,8-diazabicyclo[3.2.1]octyl, 1,4-diazabicyclo[3.2.2]nonyl, azaspiro[3.3]heptyl, 4,7-diazaspiro[2.5]octanyl, 2,6-diazaspiro[3.3]heptyl, 2,6-diazaspiro[3.4]octanyl, 1,7-diazaspiro[4.4]nonyl, 2,6-diazaspiro[3.5]nonyl, 2,7-diazaspiro[3.5]nonyl, 5,8-diazaspiro[3.5]non yl, 2,7-diazaspiro[4.4]nonyl, 2,7-diazaspiro[4.5]decanyl and 6,9-diazaspiro[4.5]decyl,
wherein, each instance of heterocyclyl is optionally substituted with one, two or three R 3 substituents and optionally, with one additional R 4 substituent, or,
wherein, alternatively, each instance of heterocyclyl is optionally substituted with one, two, three or four R 3 substituents;
R 2 is heteroaryl, selected from the group consisting of thienyl, 1H-imidazolyl, 1,3-thiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridinyl, pyrimidinyl, 1H-indolyl, 2H-indolyl, 1H-indazolyl, 2H-indazolyl, indolizinyl, benzofuranyl, benzothienyl, 1H-benzimidazolyl, 1,3-benzothiazolyl, 1,3-benzoxazolyl, 9H-purinyl, furo[3,2-b]pyridinyl, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-d]pyrimidinyl, 1H-pyrrolo[2,3-b]pyridinyl, 1H-pyrrolo[2,3-c]pyridinyl, pyrrolo[1,2-a]pyrimidinyl, pyrrolo[1,2-a]pyrazinyl, pyrrolo[1,2-b]pyridazinyl, pyrazolo[1,5-a]pyridinyl, 2H-pyrazolo[3,4-c]pyridinyl, 2H-pyrazolo[4,3-b]pyridinyl, 2H-pyrazolo[4,3-c]pyridinyl, pyrazolo[1,5-a]pyrazinyl, imidazo[1,2-a]pyridinyl, imidazo[1,2-a]pyrimidinyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, 3H-imidazo[4,5-b]pyridinyl, imidazo[2,1-b][1,3]thiazolyl, imidazo[2,1-b][1,3,4]thiadiazolyl, [1,3]oxazolo[4,5-b]pyridinyl, [1,3]oxazolo[4,5-c]pyridinyl, [1,3]thiazolo[4,5-c]pyridinyl, [1,3]thiazolo[5,4-b]pyridinyl, [1,2,4]triazolo[1,5-a]pyridinyl and quinoxalinyl,
wherein, each instance of heteroaryl is optionally substituted with one, two or three R 6 substituents and optionally, with one additional R 7 substituent;
R a is, in each instance, independently selected from the group consisting of hydrogen and C 1-8 alkyl;
R b is, in each instance, independently selected from the group consisting of hydrogen and halogen;
R 3 is, in each instance, independently selected from the group consisting of cyano, halogen, hydroxy, C 1-8 alkyl, halo-C 1-8 alkyl, C 1-8 alkyl-carbonyl, C 1-8 alkoxy, halo-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl, C 1-8 alkoxy-carbonyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, amino-C 1-8 alkyl, C 1-8 alkyl-amino-C 1-8 alkyl, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, amino-C 1-8 alkyl-amino, C 1-8 alkyl-amino-C 1-8 alkyl-amino, (C 1-8 alkyl-amino-C 1-8 alkyl) 2 -amino, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl-amino, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl] 2 -amino, (C 1-8 alkyl-amino-C 1-8 alkyl)(C 1-8 alkyl)amino, [(C 1-8 alkyl) 2 -amino-C 1-8 alkyl](C 1-8 alkyl)amino, C 1-8 alkoxy-C 1-8 alkyl-amino, (C 1-8 alkoxy-C 1-8 alkyl) 2 -amino, (C 1-8 alkoxy-C 1-8 alkyl)(C 1-8 alkyl)amino, C 1-8 alkyl-carbonyl-amino, C 1-8 alkoxy-carbonyl-amino, hydroxy-C 1-8 alkyl, hydroxy-C 1-8 alkoxy-C 1-8 alkyl, hydroxy-C 1-8 alkyl-amino, (hydroxy-C 1-8 alkyl) 2 -amino and (hydroxy-C 1-8 alkyl)(C 1-8 alkyl)amino,
R 4 is C 3-14 cycloalkyl, C 3-4 cycloalkyl-C 1-8 alkyl, C 3-14 cycloalkyl-amino, aryl-C 1-8 alkyl, aryl-C 1-8 alkoxy-carbonyl, aryl-sulfonyloxy-C 1-8 alkyl, heterocyclyl, heterocyclyl-C 1-8 alkyl, heteroaryl or heteroaryl-C 1-8 alkyl;
wherein, each instance of C 3-14 cycloalkyl, aryl, heterocyclyl and heteroaryl is optionally substituted with one, two or three R 5 substituents;
R 5 is, in each instance, independently selected from the group consisting of halogen, hydroxy, cyano, nitro, C 1-8 alkyl, halo-C 1-8 alkyl, C 1-8 alkoxy, halo-C 1-8 alkoxy, hydroxy-C 1-8 alkyl, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, (C 1-8 alkyl) 2 -amino-C 1-8 alkyl, C 1-8 alkyl-thio and heteroaryl-C 1-8 alkyl;
R 6 is, in each instance, independently selected from the group consisting of halogen, hydroxy, cyano, nitro, C 1-8 alkyl, C 2-8 alkenyl, cyano-C 1-8 alkyl, halo-C 1-8 alkyl, hydroxy-C 1-8 alkyl, C 1-8 alkoxy, halo-C 1-8 alkoxy, (C 1-8 alkyl) 2 -amino-C 1-8 alkoxy, C 1-8 alkoxy-C 1-8 alkyl, C 1-8 alkoxy-C 1-8 alkoxy, amino, C 1-8 alkyl-amino, (C 1-8 alkyl) 2 -amino, C 1-8 alkoxy-C 1-8 alkyl-amino, (C 1-8 alkoxy-C 1-8 alkyl, C 1-8 alkyl)amino and C 1-8 alkyl-thio; and,
R 7 is C 3-14 cycloalkyl, C 3-14 cycloalkyl-oxy, aryl, heterocyclyl, heteroaryl or heteroaryl-C 1-8 alkoxy, wherein the form of the compound is selected from the group consisting of a salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
2. A compound of claim 1 , wherein the form of the compound is a compound salt selected from the group consisting of hydrochloride, hydrobromide, trifluoroacetate, formate, dihydrochloride, dihydrobromide, ditrifluoracetate, diformate, trihydrochloride, trihydrobromide, tritrifluororacetate and triformate.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 18, 2025
From: WOLL, MATTHEW G.; AMEDZO, LUKIANA; BABU, SURESH; BARRAZA, SCOTT J.; BHATTACHARYYA, ANURADHA; KARP, GARY MITCHELL; MAZZOTTI, ANTHONY R.; NARASIMHAN, JANA; PATEL, JIGAR; TURPOFF, ANTHONY; XU, ZHENRONG
To: PTC THERAPEUTICS, INC.
Reel/Frame 071447/0895 →
Continuity (3)
Continuation
16617450
Provisional Application
62514999
· Jun 5, 2017
References Cited (400)
US 3558618A
· Trepanier
· 1971
[cited by applicant]
US 4122274A
· Juby
· 1978
[cited by applicant]
US 4342870A
· Kennis et al.
· 1982
[cited by applicant]
US 4613603A
· Sanofi
· 1986
[cited by applicant]
US 4902695A
· Ornstein
· 1990
[cited by applicant]
US 5089633A
· Powers et al.
· 1992
[cited by applicant]
US 5599816A
· Chu et al.
· 1997
[cited by applicant]
US 5627274A
· Kole et al.
· 1997
[cited by applicant]
US 5665593A
· Kole et al.
· 1997
[cited by applicant]
US 5916808A
· Kole et al.
· 1999
[cited by applicant]
US 5916916A
· Hauser et al.
· 1999
[cited by applicant]
US 5976879A
· Kole et al.
· 1999
[cited by applicant]
US 6172216B1
· Bennett et al.
· 2001
[cited by applicant]
US 6210892B1
· Bennett et al.
· 2001
[cited by applicant]
US 6214986B1
· Bennett et al.
· 2001
[cited by applicant]
US 6468607B1
· Takehara et al.
· 2002
[cited by applicant]
US 6630488B1
· Lamothe et al.
· 2003
[cited by applicant]
US 6977255B2
· Robertson et al.
· 2005
[cited by applicant]
US 7326711B2
· Wang et al.
· 2008
[cited by applicant]
US 7399767B2
· Zhang et al.
· 2008
[cited by applicant]
US 7473784B2
· Liu et al.
· 2009
[cited by applicant]
US 7569337B2
· Auberson
· 2009
[cited by applicant]
US 7576110B2
· Cowart et al.
· 2009
[cited by applicant]
US 7655657B2
· Stoner et al.
· 2010
[cited by applicant]
US 7897792B2
· Iikuea et al.
· 2011
[cited by applicant]
US 7910578B2
· Peters et al.
· 2011
[cited by applicant]
US 8143274B2
· Hattori et al.
· 2012
[cited by applicant]
US 8314119B2
· Schrimpf et al.
· 2012
[cited by applicant]
US 8337941B2
· Gubernator et al.
· 2012
[cited by applicant]
US 8563550B2
· Pevarello et al.
· 2013
[cited by applicant]
US 8633019B2
· Paushkin et al.
· 2014
[cited by applicant]
US 8765747B2
· Choi et al.
· 2014
[cited by applicant]
US 8846661B2
· Schrimpf et al.
· 2014
[cited by applicant]
US 8921361B2
· Cmiljanovic et al.
· 2014
[cited by applicant]
US 8940716B2
· Ye et al.
· 2015
[cited by applicant]
US 9340537B2
· Furet et al.
· 2016
[cited by applicant]
US 9371336B2
· Lee et al.
· 2016
[cited by applicant]
US 9399649B2
· Chen et al.
· 2016
[cited by applicant]
US 9617268B2
· Woll et al.
· 2017
[cited by applicant]
US 9969754B2
· Ratni et al.
· 2018
[cited by applicant]
US 20020099208A1
· Yu et al.
· 2002
[cited by applicant]
US 20030004164A1
· Bebbington et al.
· 2003
[cited by applicant]
US 20030199526A1
· Choquette et al.
· 2003
[cited by applicant]
US 20040224952A1
· Cowart et al.
· 2004
[cited by applicant]
US 20050054836A1
· Krainer et al.
· 2005
[cited by applicant]
US 20050074801A1
· Monia et al.
· 2005
[cited by applicant]
US 20050159597A1
· Ji et al.
· 2005
[cited by applicant]
US 20060172962A1
· Vickers et al.
· 2006
[cited by applicant]
US 20060205741A1
· Zhang et al.
· 2006
[cited by applicant]
US 20070078144A1
· Stockwell et al.
· 2007
[cited by applicant]
US 20070105807A1
· Sazani et al.
· 2007
[cited by applicant]
US 20070191374A1
· Hodgetts
· 2007
[cited by applicant]
US 20080171792A1
· Jobdevairakkam et al.
· 2008
[cited by applicant]
US 20080255162A1
· Bruendl et al.
· 2008
[cited by applicant]
US 20090163464A1
· Black et al.
· 2009
[cited by applicant]
US 20090163515A1
· Birault et al.
· 2009
[cited by applicant]
US 20090170793A1
· Gaur
· 2009
[cited by applicant]
US 20090264433A1
· Russell et al.
· 2009
[cited by applicant]
US 20100004233A1
· Iikura et al.
· 2010
[cited by applicant]
US 20100035279A1
· Gubernator et al.
· 2010
[cited by applicant]
US 20100267721A1
· Hohlweg et al.
· 2010
[cited by applicant]
US 20110086833A1
· Paushkin et al.
· 2011
[cited by applicant]
US 20110118289A1
· Giordani et al.
· 2011
[cited by applicant]
US 20120083495A1
· Heemskerk et al.
· 2012
[cited by applicant]
US 20130046093A1
· Lee et al.
· 2013
[cited by applicant]
US 20140051672A1
· Cheung et al.
· 2014
[cited by applicant]
US 20150018301A1
· Lee et al.
· 2015
[cited by applicant]
US 20150057218A1
· Zhong et al.
· 2015
[cited by applicant]
US 20170001995A1
· Metzger et al.
· 2017
[cited by applicant]
US 20180282347A1
· Arlt et al.
· 2018
[cited by applicant]
US 20190264267A1
· Yang et al.
· 2019
[cited by applicant]
US 20200080083A1
· Vargeese et al.
· 2020
[cited by applicant]
CN 101360738A
· 2009
[cited by applicant]
CN 102971311A
· 2013
[cited by applicant]
CN 103533835A
· 2014
[cited by applicant]
CN 101426772A
· 2014
[cited by applicant]
CN 104768960B
· 2017
[cited by applicant]
DE 2345064A1
· 1974
[cited by applicant]
EP 1227084A1
· 2002
[cited by applicant]
EP 2560008A2
· 2013
[cited by applicant]
EP 2841428B1
· 2018
[cited by applicant]
FR 2914188A1
· 2008
[cited by applicant]
GB 1047935A
· 1966
[cited by applicant]
GB 1383409
· 1975
[cited by applicant]
JP S5852307A
· 1983
[cited by applicant]
JP S6136282
· 1986
[cited by applicant]
JP 2006219453A
· 2006
[cited by examiner]
JP 2009508957A
· 2009
[cited by applicant]
JP 2009545540
· 2009
[cited by applicant]
JP 2012530071A
· 2012
[cited by applicant]
JP 201340945
· 2013
[cited by applicant]
JP 2017512834
· 2017
[cited by applicant]
JP 2017533237A
· 2017
[cited by applicant]
WO 1993023398A1
· 1993
[cited by applicant]
WO 1994026877A1
· 1994
[cited by applicant]
WO 1996039407A1
· 1996
[cited by applicant]
WO 1998025930A1
· 1998
[cited by applicant]
WO 2001053266A1
· 2001
[cited by applicant]
WO 2002062290A2
· 2002
[cited by applicant]
WO 2002087589A1
· 2002
[cited by applicant]
WO 2004009558A1
· 2004
[cited by applicant]
WO 2004019002A2
· 2004
[cited by applicant]
WO 2004029053A1
· 2004
[cited by applicant]
WO 2004043458A1
· 2004
[cited by applicant]
WO 2004113335A2
· 2004
[cited by applicant]
WO 2005012288A1
· 2005
[cited by applicant]
WO 2005019215A1
· 2005
[cited by applicant]
WO 2005061513A1
· 2005
[cited by applicant]
WO 2005066166A2
· 2005
[cited by applicant]
WO 2005072720A1
· 2005
[cited by applicant]
WO 2005105801A1
· 2005
[cited by applicant]
WO 2006131835A2
· 2006
[cited by applicant]
WO 2006138418A2
· 2006
[cited by applicant]
WO 2007003604A2
· 2007
[cited by applicant]
WO 2007016392A2
· 2007
[cited by applicant]
WO 2007018738A1
· 2007
[cited by applicant]
WO 2007047913A2
· 2007
[cited by applicant]
WO 2007056580A2
· 2007
[cited by applicant]
WO 2007065892A1
· 2007
[cited by applicant]
WO 2007071055A1
· 2007
[cited by applicant]
WO 2007089584A2
· 2007
[cited by applicant]
WO 2007089611A2
· 2007
[cited by applicant]
WO 2007090073A2
· 2007
[cited by applicant]
WO 2007109211A2
· 2007
[cited by applicant]
WO 2007110364A1
· 2007
[cited by applicant]
WO 2007130383A2
· 2007
[cited by applicant]
WO 2007133561A2
· 2007
[cited by applicant]
WO 2007133756A2
· 2007
[cited by applicant]
WO 2007135121A1
· 2007
[cited by applicant]
WO 2008011109A2
· 2008
[cited by applicant]
WO 2008014822A1
· 2008
[cited by applicant]
WO 2008020302A2
· 2008
[cited by applicant]
WO 2008049864A1
· 2008
[cited by applicant]
WO 2008077188A1
· 2008
[cited by applicant]
WO 2009042907A1
· 2009
[cited by applicant]
WO 2009085945A1
· 2009
[cited by applicant]
WO 2009114874A2
· 2009
[cited by applicant]
WO 2009126635A1
· 2009
[cited by applicant]
WO 2009151546A2
· 2009
[cited by applicant]
WO 2009156861A2
· 2009
[cited by applicant]
WO 2010000032A1
· 2010
[cited by applicant]
WO 2010019236A1
· 2010
[cited by applicant]
WO 2010024903A1
· 2010
[cited by applicant]
WO 2010045303A2
· 2010
[cited by applicant]
WO 2010071819A1
· 2010
[cited by applicant]
WO 2010093425A1
· 2010
[cited by applicant]
WO 2010130934A2
· 2010
[cited by applicant]
WO 2010145208A1
· 2010
[cited by applicant]
WO 2011032045A1
· 2011
[cited by applicant]
WO 2011050245A1
· 2011
[cited by applicant]
WO 2011057204A2
· 2011
[cited by applicant]
WO 2011062853A1
· 2011
[cited by applicant]
WO 2011085990A1
· 2011
[cited by applicant]
WO 2011097641A1
· 2011
[cited by applicant]
WO 2011097643A1
· 2011
[cited by applicant]
WO 2011097644A2
· 2011
[cited by applicant]
WO 2012012467A2
· 2012
[cited by applicant]
WO 2012019106A2
· 2012
[cited by applicant]
WO 2012075393A2
· 2012
[cited by applicant]
WO 2012103806A1
· 2012
[cited by applicant]
WO 2012104823A2
· 2012
[cited by applicant]
WO 2012109395A1
· 2012
[cited by applicant]
WO 2012116965A1
· 2012
[cited by applicant]
WO 2013019938A1
· 2013
[cited by applicant]
WO 2013020993A1
· 2013
[cited by applicant]
WO 2013022990A1
· 2013
[cited by applicant]
WO 2013033223A1
· 2013
[cited by applicant]
WO 2013059606A1
· 2013
[cited by applicant]
WO 2013068769A1
· 2013
[cited by applicant]
WO 2013101974A1
· 2013
[cited by applicant]
WO 2013112788A1
· 2013
[cited by applicant]
WO 2013119916A1
· 2013
[cited by applicant]
WO 2013130689A1
· 2013
[cited by applicant]
WO 2013142236A1
· 2013
[cited by applicant]
WO 2013151877A1
· 2013
[cited by applicant]
WO 2013163190A1
· 2013
[cited by applicant]
WO 2014012050A2
· 2014
[cited by applicant]
WO 2014028459A1
· 2014
[cited by applicant]
WO 2014059341A2
· 2014
[cited by applicant]
WO 2014059356A2
· 2014
[cited by applicant]
WO 2014066836A1
· 2014
[cited by applicant]
WO 2014069675A1
· 2014
[cited by applicant]
WO 2014116845A1
· 2014
[cited by applicant]
WO 2014121287A2
· 2014
[cited by applicant]
WO 2014135244A1
· 2014
[cited by applicant]
WO 2014184163A1
· 2014
[cited by applicant]
WO 2014209841A2
· 2014
[cited by applicant]
WO 2015024876A2
· 2014
[cited by applicant]
WO 2015017589A1
· 2015
[cited by applicant]
WO 2015095446A1
· 2015
[cited by applicant]
WO 2015095449A1
· 2015
[cited by applicant]
WO 2015105657A1
· 2015
[cited by applicant]
WO 2015107425A2
· 2015
[cited by applicant]
WO 2015107494A1
· 2015
[cited by applicant]
WO 2015110446A1
· 2015
[cited by applicant]
WO 2017080967A1
· 2015
[cited by applicant]
WO 2015143185A1
· 2015
[cited by applicant]
WO 2015173181A1
· 2015
[cited by applicant]
WO 2015197503A1
· 2015
[cited by applicant]
WO 2016071283A1
· 2016
[cited by applicant]
WO 2016087417A1
· 2016
[cited by applicant]
WO 2016128343A1
· 2016
[cited by applicant]
WO 2016131776A1
· 2016
[cited by applicant]
WO 2016144351A1
· 2016
[cited by applicant]
WO WO2016170163A1
· 2016
[cited by examiner]
WO 2016184832A1
· 2016
[cited by applicant]
WO 2017023987A1
· 2017
[cited by applicant]
WO 2017081111A1
· 2017
[cited by applicant]
WO 2017097728A1
· 2017
[cited by applicant]
WO 2017100726A1
· 2017
[cited by applicant]
WO 2017153601A1
· 2017
[cited by applicant]
WO 2017175068A1
· 2017
[cited by applicant]
WO 2017189829A1
· 2017
[cited by applicant]
WO 2017210134A1
· 2017
[cited by applicant]
WO 2018013770A1
· 2018
[cited by applicant]
WO 2018081091A1
· 2018
[cited by applicant]
WO 2018187209A1
· 2018
[cited by applicant]
WO 2018218133A1
· 2018
[cited by applicant]
WO 2018226622A1
· 2018
[cited by applicant]
WO 2019005980A1
· 2019
[cited by applicant]
WO 2019005993A1
· 2019
[cited by applicant]
WO 2019028440A1
· 2019
[cited by applicant]
WO 2019165073A1
· 2019
[cited by applicant]
WO 2019183364A1
· 2019
[cited by applicant]
WO 2019183367A1
· 2019
[cited by applicant]
WO 2019191092A1
· 2019
[cited by applicant]
WO 2019191229A1
· 2019
[cited by applicant]
WO 2020005873A1
· 2020
[cited by applicant]
WO 2020005877A1
· 2020
[cited by applicant]
WO 2020005882A1
· 2020
[cited by applicant]
WO 2020190793A1
· 2020
[cited by applicant]
WO 2020231977A1
· 2020
[cited by applicant]
WO 2021007378A1
· 2021
[cited by applicant]
WO 2021084495A1
· 2021
[cited by applicant]
WO 2021174163A1
· 2021
[cited by applicant]
WO 2021207453A1
· 2021
[cited by applicant]
WO 2022103980A1
· 2022
[cited by applicant]
WO 2023009816A1
· 2023
[cited by applicant]
WO 2023244996A2
· 2023
[cited by applicant]
Berge et al. “Pharmaceutical Salts”. Journal of Pharmaceutical Sciences. 66(1):1-19. (Year: 1977).
[cited by examiner]
Brunhilde Wirth et al., “Moving towards treatments for spinal muscular atrophy: hopes and limits”, Expert Opinion on Emerging drugs, 20(3):353-356, Apr. 28, 2015.
[cited by applicant]
Cheung et al., “Discovery of Small Molecule Splicing Modulators of Survival Motor Neuron-2 (SMN2) for the Treatment of Spinal Muscular Atrophy (SMA)”, J. Med. Chem. vol. 61(24):11021-11036, Nov. 8, 2018 (published), pp.…
[cited by applicant]
Chiara Zanetta et al., “Molecular Therapeutic Strategies for Spinal Muscular Atrophies: Current and Future Clinical Trials”, Clinical Therapeutics, 36(1):128-140, Dec. 17, 2013.
[cited by applicant]
Coady et al., 2010, “Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy”, J. Neurosci., vol. 30(1), pp. 126-130, 2010.
[cited by applicant]
Combrink et al., “Respiratory syncytial virus fusion inhibitors. Part 6: An examination of the effect of structural variation for the benzimidazol-2-one heterocycle moiety”, Bioorganic & Medicinal Chemistry Letters, 17(…
[cited by applicant]
European Patent Office, Communication pursuant to Article 94(3) EPC, European Application No. 14877918.4, date of mailing Mar. 23, 2018.
[cited by applicant]
Greene, Protective Groups in Organic Syntehsis, 1991, Wiley, New York, pp. v-xxi and 1-17.
[cited by applicant]
H. Kubinyi, “3D QSAR in Drug Design—Theory Methods and Applications”, pp. vii-ix and pp. 243-244, 1998.
[cited by applicant]
Higuchi and V. Stella, “Pro-drugs as novel delivery systems”, vol. 14 of the A.C.S., Symposium Series and in Bioreversible Carriers in Drug Design, ed., Edward B. Roche, American Pharmaceutical Association and Pergamon …
[cited by applicant]
Hua et al., “Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model”, Nature, vol. 478(7367), pp. 123-126, 2012.
[cited by applicant]
Jarecki et al., “Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy”, Human molecular genetics, 14(14):2003-201…
[cited by applicant]
Knight et al., “Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold”,
[cited by applicant]
Kocar, Transformations of 3-aminopyridazines. Synthesis of 4-oxo-4H-pyrimido [1,2-b]pyridazine and 1-(substituted pyridazin-3-yl)-1H-1,2,3-triazole derivatives, Arkivoc, vol. 8, 2002, 143-156.
[cited by applicant]
Lazarev et al., “Factors Affecting Aggregate Formation in Cell Models of Huntington's Disease and Amyotrophic Lateral Sclerosis”,
[cited by applicant]
Le et al., “SMND7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN”, Human Molecular Genetics, vol. 14(5)…
[cited by applicant]
Liu et al., “A novel nuclear structure containing the survival of motor neurons protein”, EMBO J. vol. 15(14), pp. 3555-3565 (1996).
[cited by applicant]
MacDonald et al., “Quantification Assays for Total and Polyglutamine-Expanded Huntington Proteins”, PLOS One, 2014, vol. 9(5), published May 9, 2014, pp. 1-17.
[cited by applicant]
Makhortova et al., “A screen for regulators of survival of motor neuron proteins levels”, Nature chemical biology, vol. 7(8):544-552, 2011.
[cited by applicant]
Markus Riessland et al., “The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells”, Hum Genet 120:101-110, May 26, 2006.
[cited by applicant]
Naryshkin et al., “SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy”, Science, vol. 345(6197):688-693, 2014 (including supplementary materials).
[cited by applicant]
Palacino et al., “SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice”, Nature: Chemical Biology, pp. 511-517 and 5 Supplemental pp. +S1-S20, vol. 11, Jun. 1, 2015.
[cited by applicant]
Passini et al., “Antisense Oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy”, Sci Transl. Med., vol. 3(72), 2001.
[cited by applicant]
Peng, Lijie et al., “Identification of pyrido[1,2-alpha]pyrimidine-4-ones as new molecules improving the transcriptional functions of estrogen-related receptor alpha”, Journal of medicinal chemistry, vol. 54(21):7729-77…
[cited by applicant]
Potkin et al., “New directions in therapeutics for Huntington disease”, Future Neurology, vol. 13(2):101-121, May 2018.
[cited by applicant]
Pryor et al., “Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease”, Sci. Signal, dated Oct. 28, 2014, 2014, vol. 7, Issue 349, ra103, pp. 1-12.
[cited by applicant]
PubChem/NCBI Database accession No. CID 377422 [online], 2005, retrieved on Jul. 4, 2016, URL http://pubchem.nci.nlm.nih.gov/compound/377422.
[cited by applicant]
Seisuke Mimori et al., “Protective Effects of 4-phenylbutyrate derivatives on the neuronal cell death and endoplasmic reticulum stress,” Biological & Pharmaceutical Bulletin of Japan, 35(1):84-90, Jan. 1, 2012.
[cited by applicant]
Shao, Ning et al., “Synthesis and structure-activity relationship (SAR) study of 4-azabenzoxazole analogues as H3 antagonists”, Bioorganic & Medicinal chemistry letters, vol. 22(5):2075-2078, 2012.
[cited by applicant]
Sin et al., “Respiratory syncytial virus fusion inhibitors. Part 7: Structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo”, Bioorganic & Medicinal Chemist…
[cited by applicant]
Yuo et al., 2008, “5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells”, Annals of neurology, vol. 63(1):26-34, 2008.
[cited by applicant]
Wermuth, “The Practice of Medicinal Chemistry”, 2nd ed., 2003, Chapters 9-10.
[cited by applicant]
Pubchem, Substance Record for SID 249779947, Mar. 31, 2015, “4H-Quinolizin-4one1; Hydrobromide”.
[cited by applicant]
International Search Report for PCT/EP2012/065499, mailed Sep. 28, 2012.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/EP2012/065499, mailed Sep. 28, 2012.
[cited by applicant]
International Search Report for PCT/EP2014/059699, mailed Aug. 25, 2014.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/EP2014/059699, mailed Aug. 25, 2014.
[cited by applicant]
International Search Report for PCT/EP2015/051066, mailed Feb. 19, 2015.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/EP2015/051066, mailed Feb. 19, 2015.
[cited by applicant]
International Search Report for PCT/EP2015/060343, mailed Jul. 13, 2015.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/EP2015/060343, mailed Jul. 13, 2015.
[cited by applicant]
International Search Report for PCT/EP2016/060952, mailed Jun. 29, 2016.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/EP2016/060952, mailed Jun. 29, 2016.
[cited by applicant]
International Search Report for PCT/EP2016/076905, mailed Feb. 9, 2017.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/EP2016/076905, Feb. 9, 2017.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/EP2016/077190, mailed Mar. 1, 2017.
[cited by applicant]
International Search Report for PCT/EP2016/077190, mailed Mar. 1, 2017.
[cited by applicant]
International Search Report for PCT/EP2016/079816, mailed Jan. 19, 2017.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/EP2016/079816, mailed Jan. 19, 2017.
[cited by applicant]
International Search Report for PCT/US2013/025292, mailed Aug. 30, 2013.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/US2013/025292, mailed Aug. 30, 2013.
[cited by applicant]
International Search Report for PCT/US2016/066042, mailed Mar. 16, 2017.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/US2016/066042, mailed Mar. 16, 2017.
[cited by applicant]
International Search Report for PCT/US2018/035954, mailed Oct. 1, 2018.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/US2018/035954, mailed Oct. 1, 2018.
[cited by applicant]
International Search Report for PCT/US2018/039775, mailed Oct. 29, 2018.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/US2018/039775, mailed Oct. 29, 2018.
[cited by applicant]
International Search Report for PCT/US2018/039794, mailed Oct. 25, 2018.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/US2018/039794, mailed Oct. 25, 2018.
[cited by applicant]
International Search Report for PCT/US2019/024068, mailed Jul. 10, 2019.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/US2019/024068, mailed Jul. 10, 2019.
[cited by applicant]
International Search Report for PCT/US2019/024278, mailed May 28, 2019.
[cited by applicant]
Written Opinion of the International Searching Authority in PCT/US2019/024278, mailed May 28, 2019.
[cited by applicant]
Andreassi, C. et al. 2001. Human Molecular Genetics 10, 2841-2849. “Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients.”
[cited by applicant]
Artursson P., et al. 1991. Biochem Biophys Res Comm 175, 880-5. “Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.”
[cited by applicant]
Baldo, B. et al. 2012. J. Biol. Chem. 287, 1406-1414. “A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein.”
[cited by applicant]
Barbaro, B.A. et al. 2015. Human Molecular Genetics 24, 913-925 (published online Oct. 9, 2014). “Comparative study of naturally occurring huntingtin fragments in
[cited by applicant]
Bates, G.P. et al. 2015. Nature Reviews, Disease Primers 1, 15005 (published online Apr. 23, 2015). “Huntington disease.”
[cited by applicant]
Bengart, P. et al. 2004. Nucleic Acids Res. 32, W154-W159. “Riboswitch finder—a tool for indentification of riboswitch RNAs.”
[cited by applicant]
Bhattacharyya, A. et al. 2007 Drug Discovery Today 12, 553-560. “Mining the GEMS—a novel platform technology targeting post-transcriptional control mechanisms.”
[cited by applicant]
Bibillo, A and Eickbush, T.H. 2002. J. Biol. Chem. 277, 34836-34845. “High Processivity of the Reverse Transcriptase from a Non-long Terminal Repeat Retrotransposon.”
[cited by applicant]
Carroll, J.B. et al. 2015. Lancet Neurol 14, 1135-1142 (No. 11—Nov. 2015). “Treating the whole body in Huntington's disease.”
[cited by applicant]
Cartegni, L. et al. 2003. Nucleic Acids Res. 31, 3568-3571. “ESEfinder: a web resource to identify exonic splicing enhancers.”
[cited by applicant]
Crooks, G. E., et al. 2004. Genome Research 14, 1188-1190. “WebLogo: a sequence logo generator.”
[cited by applicant]
Daguenet et al. 2015. EMBO reports 16, 1640-1655 (published online Nov. 13, 2015). “The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.”
[cited by applicant]
DiFiglia, et al 1997. Science 277, 1990-1993. “Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain”.
[cited by applicant]
Dobin, A. et al. 2013. Bioinformatics 29, 15-21. “STAR: ultrafast universal RNA-seq aligner.”
[cited by applicant]
Evers, M.M. et al. 2015. Molecular Neurodegeneration 10, Article No. 21 (published online Apr. 28, 2015). “Making (anti-) sense out of huntingtin levels in Huntington disease.”
[cited by applicant]
Fardaei, M. et al. 2002. Human Molecular Genetics 11, 805-814. “Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells.”
[cited by applicant]
Fernandez-Nogales, M. et al. 2014. Nature Medicine 20, 881-885. “Huntington's disease is a four-repeat tauopathy with tau nuclear rods.”
[cited by applicant]
Gipson, T. A. et al. 2013. RNA Biology 10, 1647-1652. “Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis.”
[cited by applicant]
Gray, M. et al. 2008. J. Neurosci. 28, 6182-6195. “Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.”
[cited by applicant]
Griffiths-Jones, S. et al. 2005. Nucleic Acids Res. 33, D121-D124. “Rfam: annotating non-coding RNAs in complete genomes.”
[cited by applicant]
Griffiths-Jones, S. et al. 2006. Nucleic Acids Res. 34, D140-D144. “miRBase: microRNA sequences, targets and gene nomenclature.”
[cited by applicant]
Grillo, G. et al. 2003. Nucleic Acids Res. 31, 3608-3612. “PatSearch: a program for the detection of patterns and structural motifs in nucleotide sequences.”
[cited by applicant]
Grimson, A. et al. 2007. Molecular Cell 27, 91-105. “MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing.”
[cited by applicant]
Heemskerk, J. et al. 2002. Nature Neuroscience Supplement 5, 1027-1029. “From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials.”
[cited by applicant]
Heemskerk, J, et al. 2002. Trends Neurosci. 25, 494-496. “Teaching old drugs new tricks.”
[cited by applicant]
Heemskerk, J. et al. 2005. Chapter 16—“Therapeutics Development for Hereditary Disorders” in ed. Waxman, S. From Neuroscience to Neurology: Neuroscience, Molecular Medicine, and the Therapeutic Transformation of Neurolo…
[cited by applicant]
Hernandez-Imas, E. et al. 2015. PLoS One 10, e141735 (published online Oct. 28, 2015). “Functional Analysis of Mutations in Exon 9 of NF1 Revales the Presence of Several Elements Regulating Splicing.”
[cited by applicant]
Hodges, A. et al. 2006. Human Molecular Genetics 15, 965-977. “Regional and cellular gene expression changes in human Huntington's disease brain.”
[cited by applicant]
Hua et al. 2007. PLoS Biol 5, e73. Enhancement of SMN2 Exon 7 “Inclusion by Antisense Oligonucleotides Targeting the Exon.”
[cited by applicant]
Hua et al. 2008. American J. of Human Genetics 82, 834-848. “Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice.”
[cited by applicant]
The Huntington's Disease Collaborative Research Group, 1993, Cell, 72, pp. 971-983 (1993). “A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's Disease chromosomes.”
[cited by applicant]
Janas, A. M. 2015. “A Stem Cell Model of the Motor Circuit Reveals Distinct Requirements for SMN in Motor Neuron Survival and Function.”
[cited by applicant]
Jacobs, G.H. et al. 2006. Nucleic Acids Res. 34, suppl_1, D37-D40. “Transterm—extended search facilities and improved integration with other databases.”
[cited by applicant]
Kanadia, R.N. et al. 2003. Science 302, 1978-1980. “A Muscleblind Knockout Model for Myotonic Dystrophy.”
[cited by applicant]
Kaplan, A. et al. 2012. Prog. Neurobiol. 99(3), 262-280. “Therapeutic approaches to preventing cell death in Huntington disease.”
[cited by applicant]
Kim, D. et al. 2013. Genome Biology 14, Article No. R36. “TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions.”
[cited by applicant]
Kordasiewicz, H.B. et al. 2012. Neuron, 74, 1031-1044. “Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis”.
[cited by applicant]
Kuhn, A. et al. 2007. Human Molecular Genetics 16, 1845-1861. “Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mut…
[cited by applicant]
Labadorf, A.T. et al. 2015. Plos One 10(10): e0141298 (published online Oct. 23, 2015). “Evidence of Extensive Alternative Splicing in Post Mortem Human Brain HTT Transcription by mRNA Sequencing.” (including supplement…
[cited by applicant]
Labadorf, A. et al. 2015. PLoS One 10(12): e0143563 (published online Dec. 4, 2015). “RNA Sequence Analysis of Human Huntington Disease Brain Reveals an Extensive Increase in Inflammatory and Developmental Gene Expressi…
[cited by applicant]
Labbadia, J. et al. 2013. Trends Biochem. Sci. 38, 378-385. “Huntington's disease: underlying molecular mechanisms and emerging concepts.”
[cited by applicant]
Landles, C. et al. 2010. J. Bio. Chem. 285, 8808-8823. “Protoelysis of Mutant Huntington Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease.”
[cited by applicant]
Lei, et al. 2005. Nucleic Acids Res 33, 3897-3909. “Exonization of AluYa5 in the human ACE gene requires mutations in both 3′ and 5′ splice sites and is facilitated by a conserved splicing enhancer.”
[cited by applicant]
Liang, Y. et al. 2009. Brain Res. 2009 1286, 221-229. “ATF3 plays a protective role against toxicity by N-terminal fragment of mutant huntingtin in stable PC12 cell line.”
[cited by applicant]
Love, M. I. et al. 2014. Genome Biology 15, 550. “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.”
[cited by applicant]
Lunkes, A. et al. 2002. Molecular Cell 10, 259-269. “Proteases Acting on Mutant Huntingtin Generate Cleaved Products that Differentially Build Up Cytoplasmic and Nuclear Inclusions.”
[cited by applicant]
Macke, T.J. 2001. Nucleic Acids Res. 29, 4724-4735. “RNAMotif, an RNA secondary structure definition and search algorithm.”
[cited by applicant]
Mahmood, I. et al. 1996. Xenobiotica 26, 887-895. “Interspecies scaling: predicting clearance of drugs in humans. Three different approaches.”
[cited by applicant]
Mahmood, I. 2006. Pharm. Sci. 95, 1810-1821. “Prediction of human drug clearance from animal data: Application of the rule of exponents and ‘fu corrected intercept method’ (FCIM).”
[cited by applicant]
Mahmoudi, S et al. 2010. PLoS Biology 8(11), e10000521. “WRAP53 is Essential for Cajal Body and for Targeting the Survival of Motor Neuron Complex to Cajal Bodies.”
[cited by applicant]
Mangiarini, L. 1996. Cell 87, 493-506. “Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice.”
[cited by applicant]
Mantione, K.J. et al. 2014. Med. Sci. Monit. Basic Res. 20, 138-141. “Comparing Bioinformation Gene Expression Profiling Methods: Microarray and RNA-Seq.”
[cited by applicant]
Mendoza, L.G. et al. 1999. BioTechniques 27, 778-788. “Hight-Throughput Microarray-Based Enzyme-Linked Immunosorbent Assay (ELISA).”
[cited by applicant]
Mielcarek, M. et al. 2014. PLOS Genetics 10: 8 e1004550. “Dysfunction of the CNS-Heart Axis in Mouse Models of Huntington's Disease.”
[cited by applicant]
Mignone, F. et al. 2005. Nucleic Acids Res. 33, D141-D146. “UTRdb and UTRsite: a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs.”
[cited by applicant]
Mort, M. et al. 2015. J. of Huntington's Disease 4(2 of 4), 161-171. “Huntingtin Exists as Multiple Splice Forms in Human Brain.”
[cited by applicant]
Neuder, A. et al. 2014. BMC Medical Genomics 7:60. “A common gene expression signature in Huntington's disease patient brain regions.”
[cited by applicant]
Paganetti, P. et al. 2009. ChemBioChem 10, 1678-1688. “Development of Method for the High-Throughput Quantification of Cellular Proteins.”
[cited by applicant]
Pouladi, M. et al. 2013. Nature Review Neuroscience 14, 709-721. “Choosing an animal model for the study of Huntington's disease.”
[cited by applicant]
Ratovitski, T. et al. 2012. Cell Cycle 11, 2006-2021. “Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis.”
[cited by applicant]
Reiner, A. et al. 2011. International Review of Neurobiology 98, 325-372. “Genetics and neuropathology of Huntington's disease.”
[cited by applicant]
Ruzo, A. et al. 2015. PLoS One 10, e0127678 (published online May 26, 2015). “Discovery of Novel Isoforms of Huntingtin Reveals a New Hominid-Specific Exon.”
[cited by applicant]
Sadeghian, H. et al. 2011. Arch. Neurol. 68, 650-652. “Huntington Chorea Presenting with Motor Neuron Disease.”
[cited by applicant]
Sathasivam, K. et al. 2013. Proc. Natl. Acad. Sci. 110, 2366-2370. “Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease.”
[cited by applicant]
Schilling, G. et al. 2007. J Neuropathol. Exp. Neurol. 66, 313-320. “Characterization of Huntingtin Pathologic Fragments in Human Huntington Disease, Transgenic Mice, and Cell Models.”
[cited by applicant]
Schwab, C. et al. 2008. J. Neuropathol Exp Neurol 67, 1159-1165. “Colocalization of Transactivation-Responsive DNA-Binding Protein 43 and Huntingtin in Inclusions of Huntington Disease.”
[cited by applicant]
Shlyakhtenko, L.S. et al. 2007. Nanomedicine: Nanotech., Bio., and Med. 3, 192-197. “Single-molecule selection and recovery of structure-specific antibodies using atomic force microscopy.”
[cited by applicant]
Southwell, A.L. et al. 2013. Hum. Mol. Genet. 22, 18-34. “A fully humanized transgenic mouse model of Huntington disease.”
[cited by applicant]
Stanek, L.M. et al. 2014. Human Gene Therapy 25, 461-474. “Silencing Mutant Huntingtin by Adeno-Associated Virus-Mediated RNA Interference Ameliorates Disease Manifestations in the YAC128 Mouse Model of Huntington's Dis…
[cited by applicant]
Stoilov, P. et al. 2008. Proc. Natl. Acad. Sci. 105, 11218-11223. “A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulators.”
[cited by applicant]
Taylor et al. 1999. Nat. Biotechnol. 17, 1097-1100 “Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.”
[cited by applicant]
Van der Burg, J.M.M. et al. 2009. The Lancet (Neurology) 8, 765-774. “Beyond the brain: widespread pathology in Huntington's disease.”
[cited by applicant]
Varma, H. et al. 2008. Comb Chem High Throughput Screen 11, 238-248. “High Throughput Screening for Neurodegeneration and Complex Disease Phenotypes.”
[cited by applicant]
Vickers et al., 2006. J. Immunol. 176, 3652-3661 “Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2′-O-methoxyethyl-modified oligonucleotide.”
[cited by applicant]
Wachter, A. 2014. Trends in Genetics 30, 172-181. “Gene regulation by structured mRNA elements.”
[cited by applicant]
Weiland, M. et al. 2012. Methods 56, 351-357. “Engineering of ribozyme-based riboswitches for mammalian cells.”
[cited by applicant]
Wild, E.J. et al. 2014. Movement Disorders 29, 1434-1445. “Targets for Future Clinical Trials in Huntington's Disease: What's in the Pipeline?”
[cited by applicant]
Wilton et al. 1999. Neuromuscul. Disord. 9, 330-338. “Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.”
[cited by applicant]
Xiong, H.Y. et al. 2015. Science 347, 1254806 (published online Dec. 18, 2014.) “The human splicing code reveals new insights into the genetic determinants of disease.”
[cited by applicant]
Yeo, G. et al. 2004. J. Comput. Biol. 11, 377-394. “Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals.”
[cited by applicant]
Younis et al. 2010. Molecular and Cellular Biology 30, 1718-1728. “Rapid-Response Splicing Reporter Screens Identify Differential Regulators of Constitutive and Alternative Splicing.”
[cited by applicant]
Yu, S. et al. 2014. Trends in Pharmacological Sci. 35, 53-62. “Drugging unconventional targets: insights from Huntington's disease.”
[cited by applicant]
Zona, S. et al. 2014. Biochimica et Biophysica Acta 1839, 1316-1322. “FOXM1: An emerging master regulator of DNA damage response and genotoxic agent resistance.”
[cited by applicant]